Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.41 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.41 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.41 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.41 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.41 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.41 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.41 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 12/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18960462 | 0.89 | ATP1A1 (0.40) | CYP3A4PPARGATP1A1ATP1B1ATP1A3 | |
| SCHEMBL18960416 | 0.88 | CYP3A4 (0.43) | CYP3A4PPARGATP1A1ATP1B1ATP1A3 | |
| SCHEMBL17488301 | 0.83 | CYP3A4 (0.39) | CYP3A4PPARGATP1A1ATP1B1ATP1A3 | |
| SCHEMBL17488172 | 0.81 | CYP3A4 (0.54) | CYP3A4PPARGKDM4EPOLBP2RX3 | |
| SCHEMBL18960430 | 0.78 | CYP3A4 (0.47) | CYP3A4PPARGFPR2SCN9AKDM4E | |
| SCHEMBL18960425 | 0.77 | CYP3A4 (0.50) | CYP3A4PPARGKDM4EPOLBP2RX3 | |
| SCHEMBL18960424 | 0.77 | CYP3A4 (0.46) | CYP3A4PPARGKDM4EPOLBRAB9A | |
| SCHEMBL17488004 | 0.77 | CYP3A4 (0.46) | CYP3A4PPARGFPR2SCN9AP2RX3 | |
| SCHEMBL18960427 | 0.76 | CYP3A4 (0.45) | CYP3A4PPARGKDM4EPOLBRAB9A | |
| SCHEMBL17488305 | 0.76 | LMNA (0.47) | CYP3A4P2RX3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2017-06-15 | — | — | US | disclosed |
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | ALOX5, ALOX15, ALOX12 | CYP3A4 261/4885PPARG 472/4885ATP1A1 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.